These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 32799295)

  • 1. The glycaemic personality: A SURE framework of person-centred choice in diabetes care.
    Kalra S; Iraqi H; Sahay R; Bhattacharya S
    J Pak Med Assoc; 2020 Jul; 70(7):1285-1286. PubMed ID: 32799295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative glycaemic control.
    Preiser JC
    Anaesth Crit Care Pain Med; 2018 Jun; 37 Suppl 1():S3-S4. PubMed ID: 29679767
    [No Abstract]   [Full Text] [Related]  

  • 3. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).
    Zinman B; Marso SP; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Lange M; Brown-Frandsen K; Moses A; Ocampo Francisco AM; Barner Lekdorf J; Kvist K; Buse JB;
    Diabetologia; 2018 Jan; 61(1):48-57. PubMed ID: 28913575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
    Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
    Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycaemic variability and hypoglycaemia are associated with C-peptide levels in insulin-treated type 2 diabetes.
    Christensen MB; Gæde P; Hommel E; Gotfredsen A; Nørgaard K
    Diabetes Metab; 2020 Feb; 46(1):61-65. PubMed ID: 30796973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of diabetes in metabolic syndrome].
    Pelikánova T
    Vnitr Lek; 2009; 55(7-8):637-45. PubMed ID: 19731868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review.
    Noh RM; Graveling AJ; Frier BM
    Expert Opin Pharmacother; 2011 Oct; 12(14):2161-75. PubMed ID: 21668402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial and detrimental effects of intensive glycaemic control, with emphasis on type 2 diabetes mellitus.
    Camacho P; Pitale S; Abraira C
    Drugs Aging; 2000 Dec; 17(6):463-76. PubMed ID: 11200307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The individualisation of glycaemic targets in response to patient characteristics in type 2 diabetes: a scoping review.
    Westall SJ; Narayanan RP; Watmough S; Irving G; Furlong N; McNulty S; Bujawansa S; Hardy K
    Clin Med (Lond); 2022 May; 22(3):257-265. PubMed ID: 35443970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing safe glucose-lowering in older adults with type 2 diabetes: A PeRsOn-centred ApproaCh To IndiVidualisEd (PROACTIVE) Glycemic Goals for older people: A position statement of Primary Care Diabetes Europe.
    Hambling CE; Khunti K; Cos X; Wens J; Martinez L; Topsever P; Del Prato S; Sinclair A; Schernthaner G; Rutten G; Seidu S
    Prim Care Diabetes; 2019 Aug; 13(4):330-352. PubMed ID: 30792156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
    Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal T; Hemmingsen C; Wetterslev J
    Cochrane Database Syst Rev; 2011 Jun; (6):CD008143. PubMed ID: 21678374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Goals in Diabetes.
    Melmer A; Laimer M
    Endocr Dev; 2016; 31():1-27. PubMed ID: 26824869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing awareness of hypoglycaemia in patients with type 2 diabetes treated with oral agents.
    Barnett AH; Brice R; Hanif W; James J; Langerman H
    Curr Med Res Opin; 2013 Nov; 29(11):1503-13. PubMed ID: 23952328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model.
    McEwan P; Evans M; Kan H; Bergenheim K
    Diabetes Obes Metab; 2010 May; 12(5):431-6. PubMed ID: 20415691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of therapeutic advances on hypoglycaemia in type 2 diabetes.
    Boyle PJ; Zrebiec J
    Diabetes Metab Res Rev; 2008; 24(4):257-85. PubMed ID: 18232062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on the long-acting insulin analogue glargine.
    Thisted H; Johnsen SP; Rungby J
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):1-11. PubMed ID: 16867163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Devoting attention to glucose variability and hypoglycaemia in type 2 diabetes.
    Rutter MK
    Diabetologia; 2018 Jan; 61(1):43-47. PubMed ID: 28913602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing hypoglycemia in diabetes may be more fear management than glucose management: a practical guide for diabetes care providers.
    Vallis M; Jones A; Pouwer F
    Curr Diabetes Rev; 2014; 10(6):364-70. PubMed ID: 25394991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.